Neurocrine Biosciences Inc at Cantor Global Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Josh Schimmer - Cantor Fitzgerald LP - Analyst : Yeah, a lot to cover and probably too much for the short time here. But Eric, you walked us through the evolution of the contracting strategy for INGREZZA and then some of the nuances as we get into kind of the IRA decision for AUSTEDO. Maybe you can kind of give us that snapshot again because it was just incredibly helpful.

Question: Josh Schimmer - Cantor Fitzgerald LP - Analyst : How do we now incorporate the IRA and AUSTEDO, in particular, because this is now a multidimensional almost game of chess with all of these payers thinking about, first of all, as you're submitting bids ahead of the IRA final outcome, as you negotiate through it, as you're thinking about your installed group of patients, as you're thinking about new groups of patients that you may be considering, like how do you think about navigating these next months of contracting negotiations?

Question: Josh Schimmer - Cantor Fitzgerald LP - Analyst : Is -- do you look at the final outcome for AUSTEDO as essentially defining the eventual outcome for INGREZZA because you're not that many years behind. Another important consideration, right, that this price differential may just be temporary anyways.

Question: Josh Schimmer - Cantor Fitzgerald LP - Analyst : Is that the range for '29 beyond? Or I thought it changed in 2030?

Question: Josh Schimmer - Cantor Fitzgerald LP - Analyst : One last question on this because I want to make sure we get to CRENESSITY. Just to make sure I'm understanding, once you're through the IRA yourselves, does that mean you've got 100% formulary coverage?

Question: Josh Schimmer - Cantor Fitzgerald LP - Analyst : Yeah. There are a lot of nuances maybe to unpack, another time, but I do -- because it gets really interesting. Coming to CRENESSITY though. We had a great discussion about the different kind of centers that you're targeting, the centers of excellence, the endo peds, the endo adults and kind of the rapidity of which you can tap into these unmet needs. Maybe kind of frame that for us, the proportion, the numbers of each and the progress you're making across those domains.

Question: Josh Schimmer - Cantor Fitzgerald LP - Analyst : And so you've defined the market as your estimate of the classic CAH patient population. Maybe talk a little bit about that dynamic between non-classic and classic and the potential to move into that non-classic setting and identify patients who would be suitable for CRENESSITY.

Question: Josh Schimmer - Cantor Fitzgerald LP - Analyst : Turning to a couple of pipeline updates that we're looking for this year. First, Matt, we've talked about this. We've spoken to some cerebral palsy specialists who absolutely believe that VMAT2 inhibition is very beneficial for patients with dyskinetic cerebral palsy, and I came to you with such tremendous enthusiasm having heard of this, but you've kind of been talking me down around some of the expectations. How should we be looking at that at this next Phase 3 data update for INGREZZA?

Question: Josh Schimmer - Cantor Fitzgerald LP - Analyst : And then last, osavampator, we're going to get some of that Phase 2 data disclosure, maybe a little bit ahead of what you had anticipated, what should we be looking for there? And to clarify, like you never -- you identified two doses, but never identified which was correlated to which efficacy signals. So I think most have assumed that there's an inverse dose correlation, but I don't think you ever actually said that.

Question: Josh Schimmer - Cantor Fitzgerald LP - Analyst : Yeah. I think we're out of time. Thanks to the Neurocrine team. Thanks everyone for joining us.